Objective To evaluate the therapeutic effect of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for the treatment of hepatic metastases from pancreatic neuroendocrine tumors and to analyze the survival time. Methods Twenty - eight patients with hepatic metastases from pancreatic neuroendocrine tumors were treated with TACE and/or RFA. The clinical data, including imaging findings, total survival time and progression - free survival time, were evaluated and determined, and the potential factors possibly affecting the prognosis were discussed. Results Seventy sessions of TACE were performed in 24 patients, while 11 sessions of RFA were carried out in 6 patients. The effective rate determined by imaging evaluation was 46.4%. The overall survival time and progression-free survival time were (24.6 ± 6.6) months and (17.5 ± 6.0) months respectively. The overall survival time in patients with and without coexisting extra - hepatic metastases was (15.8 ± 6.0) months and (28.7 ± 8.4) months respectively, and the difference between the two groups was statistically significant (P = 0.041). Conclusion Both transarterial chemoembolization and radiofrequency ablation are effective treatments for hepatic metastases from pancreatic neuroendocrine tumors. The presence of extra-hepatic metastases may be one of the factors that affect the patient's prognosis.%目的 评价经肝动脉化疗栓塞(TACE)和射频消融(RFA)治疗胰腺神经内分泌肿瘤肝转移患者的疗效并进行生存分析.方法 回顾28例接受TACE或(和)RFA治疗的胰腺神经内分泌肿瘤伴肝转移患者,统计治疗后影像学改变、总生存期和疾病无进展生存期,对比分析可能影响患者预后的潜在影响因素.结果 24例患者进行了70例次TACE,6例进行了11例次RFA治疗.影像学评价有效率46.4%,总生存期为(24.6 ± 6.6)个月,疾病无进展生存期为(17.5 ± 6.0)个月.影响因素中,患者有和无在除肝脏以外的远处转移灶生存期分别为(15.8 ± 6.0)个月和(28.7 ± 8.4)个月(P = 0.041).结论 TACE和RFA是胰腺神经内分泌肿瘤肝转移的有效疗法.肝脏外的远处转移灶的存在可能为影响该类患者预后的因素.
展开▼
